Literature DB >> 16238972

[Anti-fungal drugs. Current status and guidelines for their administration].

Rodrigo Fernández Alonso1, Maria Esther González García, Joaquín Fernández García, Francisco Javier Cepeda Piorno.   

Abstract

Current medicine, in its zeal to cure diseases that, to-date, have been incurable, has overcome many barriers. High-dose chemotherapy, bone marrow and solid organ transplant, haemodialysis, parenteral and enteral nutrition, and other techniques have produced longer survival and cures for seriously ill patients. Over the past few years, fungal infections have become an important factor in morbidity and mortality in patients who are not only immunocompromised but also suffering severe pathologies. Anti-fungal treatment has been enriched, recently, with new compounds that are widening the therapeutic options for many of these patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16238972     DOI: 10.1007/bf02716583

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  36 in total

Review 1.  [Prophylaxis and treatment of fungal infections in oncohematological patients].

Authors: 
Journal:  Rev Esp Quimioter       Date:  2002-12       Impact factor: 1.553

2.  [Guidelines for the treatment of invasive fungal infection. Invasive fungal infection by Candida spp. Invasive Fungal Infection Study Group (MICOMED) and Infection in Transplantation Study Group (GESITRA) of the Spanish Society for Infectious Diseases and Clinical Microbiology (SEIMC)].

Authors:  Joan Gavaldà; Isabel Ruiz
Journal:  Enferm Infecc Microbiol Clin       Date:  2003-11       Impact factor: 1.731

Review 3.  Fungal infections: current diagnosis and treatment.

Authors:  Catherine Cordonnier
Journal:  Hematol J       Date:  2004

Review 4.  The mechanism of action of terbinafine.

Authors:  N S Ryder
Journal:  Clin Exp Dermatol       Date:  1989-03       Impact factor: 3.470

Review 5.  Pradimicins: a novel class of broad-spectrum antifungal compounds.

Authors:  T J Walsh; N Giri
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

Review 6.  Clinical experience with itraconazole in systemic fungal infections.

Authors:  M Boogaerts; J Maertens
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole.

Authors:  R K Li; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

8.  A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis.

Authors:  A Villanueva; E G Arathoon; E Gotuzzo; R S Berman; M J DiNubile; C A Sable
Journal:  Clin Infect Dis       Date:  2001-10-04       Impact factor: 9.079

Review 9.  Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy.

Authors:  P Francis; T J Walsh
Journal:  Clin Infect Dis       Date:  1992-12       Impact factor: 9.079

10.  A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis.

Authors:  Alvaro Villanueva; Eduardo Gotuzzo; Eduardo G Arathoon; L Miguel Noriega; Nicholas A Kartsonis; Robert J Lupinacci; Juanita M Smietana; Mark J DiNubile; Carole A Sable
Journal:  Am J Med       Date:  2002-09       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.